RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Epidermal growth factor receptor (EGFR) family dysfunction drives tumorigenesis.
• Anti-EGFR therapies like cetuximab are used for cancer treatment but face resistance.
• Comprehensive EGFR signaling blockade may enhance efficacy and overcome resistance.

Purpose of the Study:

• To isolate and characterize a novel anti-EGFR antibody with a potent mechanism of action.
• To evaluate the efficacy of the novel antibody, YAH627, alone and in combination with cetuximab.
• To explore the therapeutic potential of YAH627 in EGFR-driven cancers.

Main Methods:

• Phage display library screening to identify novel anti-EGFR antibodies.
• In vitro and in vivo assays to assess antibody efficacy and signaling blockade.
• Epitope analysis to determine antibody binding sites on EGFR.

Main Results:

• A novel anti-EGFR antibody, YAH627, was isolated.
• YAH627 effectively inhibits EGFR activation by blocking EGFR/HER3 heterodimerization and downstream signaling.
• Epitope mapping revealed YAH627 binds to EGFR domains II and IV, inducing a silent conformation.
• Combination therapy with YAH627 and cetuximab demonstrated synergistic antitumor activity.

Conclusions:

• YAH627 represents a novel therapeutic antibody candidate targeting EGFR.
• Its unique mechanism of action, including blocking heterodimerization and inducing a silent conformation, offers a strategy to overcome cetuximab resistance.
• Combined YAH627 and cetuximab therapy shows significant potential for treating EGFR-driven cancers.